We are developing a first-in-class, oral, small molecule drug targeting a gene mutation found in over 80% of colorectal cancer patients.

We’ve already seen unprecedented activity in animal models leveraging synthetic lethality, without toxicity. And we have a clear development strategy to reach human proof of concept in 2021-2022.


people a year die from
colorectal cancer in the US.


Colorectal cancer is the 3rd leading cause of cancer deaths worldwide.


worldwide market.

Despite newer therapies such as EGFR, VEGF inhibitors & immuno-oncology agents, CRC remains a deadly disease with ~50,000 deaths annually in the US alone. With the need for newer treatment options in this patient population, the worldwide market opportunity is ~$10 Billion.

Our Drug: TASIN

TASIN is lethal for mutated APC cancer cells, while having virtually no effect on normal cells.

TASIN has shown to be highly potent, resulting in significant inhibition of CRC tumor growth, with no apparent toxicity to normal cells.

We have fantastic binding data between TASIN and EBP which has been confirmed using multiple approaches including use of CRISPR technology.

"We expect TASIN to be in the clinic in 2021, with human proof of concept in 2021-2022. There are also some very interesting opportunities for TASIN in de-myelinating diseases — such as multiple sclerosis. We’re currently seeking investors to reach a key value inflection point."

Neil Thapar

CEO & Chief Scientific Officer